Home
[an error occurred while processing this directive]
Quality survey Health benefits Safety Reading labels Ask the supplier Standards & regulations



Editorials





Testing news
Search
Links
Glossary
Glossary
Ask the expert
Bookstore
Sponsorship
Contact us
Disclaimer
Privacy policy
Sponsorship
 

Research news

Kibow Biotech Continues Research On Therapy For Renal Disease.
Philadelphia PA, 17 November 2003
by Wyn Snow, Managing Editor

Kibow Biotech's mission is to provide a simple to use, orally ingested, friendly microbial and cost effective alternative treatment for renal disease. The product will launch in July 2004. The company is developing two distinct but highly integrated medical breakthrough products. These are:

A biopharmaceutical to be used as a complementary or adjunct therapeutic drug for treating end-stage renal failure patients who require dialysis treatment. A nutraceutical dietary management product that will help augment normal, healthy renal function for chronic kidney disease (CKD) or diminished kidney function patients (pre-dialysis patients).

Kibow's project, "A dietary supplement to augment kidney function" (Grant # 5 R44 DK061873-03) has received its second year of phase II funding by NIH. This continuation of its fast-track phase I and II Small Business Innovation Research Grant (SBIR) is funded by the National Institute of Diabetes Digestive and Kidney Diseases (NIDDK), a division of the National Institute of Health.

With the current award, Kibow has thus far secured a total of $1.9 million grant funding from the federal governmental resources. After successful completion of the phase II first year research and its progress, NIDDK, NIH has showed their continued interest in Kibow's intriguing and innovative method to treat uremia by awarding the last portion of the phase II award of $500,000 from the original $1,076,056 grant. The company was already a recipient of an earlier SBIR phase I and II fast-track grant award of $850,000 for the project entitled "Sorbents & Engineered Bacteria as Gut-Based Uremia Therapy."

The company was founded in October 1997 and is headquartered at the science center in close proximity to University of Pennsylvania/Drexel University, Philadelphia, PA. For more scientific information contact Dr. N. Ranganathan, Sr. VP (R&D) and Chief Scientific Officer at 215-966-6169.

Source

Kibow Biotech, Inc. (www.kibowbiotech.com).end-of-story

 

   
[an error occurred while processing this directive]
Health benefits Safety Reading labels Ask the supplier Standards & regulations Contact us

(c) Copyright 1999-2003 Dietary Supplement Quality Initiative. For permission to reprint, please contact our editor.